AgingResearch.NewsJoin free

Early filling rate indexed to end-diastolic volume

There is 1 paper on early filling rate indexed to end-diastolic volume in aging research: 1 trial in people. The newest story, Nov 8, 2026: “Semaglutide improved heart filling in obesity-related heart failure”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on early filling rate indexed to end-diastolic volume

  • Human trial1

Interventions

1

Semaglutide

upin humans1

1 study

  1. Semaglutide increases early filling rate indexed to end-diastolic volume in humans (obesity-related HFpEF; compared with placebo) (+0.64 s−1 (95% CI +0.42 to +1.00)).

    “and eFR/EDV (+0.64 s−1 [95% CI, +0.42 to +1.00]; P<0.0001).”

    Human trialobesity-related HFpEF; compared with placeboleft ventricle52 weeksn = 49

    Semaglutide improved heart filling in obesity-related heart failure

    Nature medicine

More on Semaglutide

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Nature Medicine

Semaglutide improved heart filling in obesity-related heart failure

Semaglutide improved how much the heart’s upper left chamber stretched by 5.7 percentage points versus placebo over 52 weeks in a 49-person trial substudy.Semaglutide improved how much the heart’s upper left chamber stretched by 5.7 percentage points versus placebo over 52 weeks in a 49-person trial substudy.

Randomized trial · 49 peopleSemaglutide
Paper

Related